-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 30, Livzon Group issued an announcement stating that the company’s Class 2 new drug Alanorelin Acetate Microspheres for Injection has been approved for clinical trials, and the indication is prostate cancer.
In addition, according to the data on the NMPA official website, the company’s Acetic Acid for Injection The application for the listing of Xiquruike 4 types of imitations has entered the approval stage, and it is expected to win the second domestic product + first review of the product
.
In addition, according to the data on the NMPA official website, the company’s Acetic Acid for Injection The application for the listing of Xiquruike 4 types of imitations has entered the approval stage, and it is expected to win the second domestic product + first review of the product
.
17 million Xiti new drug clinical approval
Figure 1: Livzon’s latest clinical product information approved
Source: CDE official website
It is reported that Livzon’s Alanorelin Acetate Microspheres for Injection is an improved new drug that has undergone 4 years of research and development.
This product is a gonadotropin releasing hormone agonist injected subcutaneously once a month, which can reduce the frequency and medication of patients.
Burden
.
This product is a gonadotropin releasing hormone agonist injected subcutaneously once a month, which can reduce the frequency and medication of patients.
Burden
.
The company has the approval of Alanorelin Acetate API.
Through the optimization of the dosage form, the company has developed long-acting sustained-release microspheres (Class 2.
2 new drugs).
At the same time, it is researching and developing new indications (Class 2.
4 new drugs).
This time, it has been approved for clinical indications.
For prostate cancer, the follow-up can also apply for the treatment of endometriosis, uterine fibroids, breast cancer, precocious puberty, assisted reproduction and other indications
.
Livzon mentioned in the announcement that up to now, the cumulative direct investment in research and development costs of Alanisterrel Acetate Microspheres for Injection is about 17,818,500 yuan
.
Through the optimization of the dosage form, the company has developed long-acting sustained-release microspheres (Class 2.
2 new drugs).
At the same time, it is researching and developing new indications (Class 2.
4 new drugs).
This time, it has been approved for clinical indications.
For prostate cancer, the follow-up can also apply for the treatment of endometriosis, uterine fibroids, breast cancer, precocious puberty, assisted reproduction and other indications
.
Livzon mentioned in the announcement that up to now, the cumulative direct investment in research and development costs of Alanisterrel Acetate Microspheres for Injection is about 17,818,500 yuan
.
The 60% soaring injection will welcome the second and first domestic review
Picture 2: Livzon's product information for approval
Source: NMPA official website
Livzon’s application for the imitation of Cetrorelix Acetate for injection in Category 4 has recently entered the approval process, and if it is successfully approved, it will become the second domestic company + the first company to review it
.
.
It is reported that Cetrorelix is a synthetic gonadotropin-releasing hormone (GnRH) antagonist (GnRH-A) drug, which prevents premature ovulation in patients undergoing controlled ovarian stimulation, and then performs egg collection and assisted reproductive technology Treatment
.
Studies have shown that Cetrorelix also has a good effect on ovarian cancer, prostate cancer, uterine fibroids, endometriosis and other diseases, and has a preventive effect on benign prostatic hypertrophy and ovarian hyperstimulation syndrome
.
.
Studies have shown that Cetrorelix also has a good effect on ovarian cancer, prostate cancer, uterine fibroids, endometriosis and other diseases, and has a preventive effect on benign prostatic hypertrophy and ovarian hyperstimulation syndrome
.
The original research company of Cetrorelix Acetate for Injection is Merck Serono, which entered the Chinese market in 2010
.
Shenzhen Hanyu Pharmaceutical's 6 types of imitation listing applications were approved in 2018, which is the first imitation in China
.
At present, Cetrorelix Acetate for injection in the domestic market has only the original research drug and one generic drug, and the competition pattern is good
.
.
Shenzhen Hanyu Pharmaceutical's 6 types of imitation listing applications were approved in 2018, which is the first imitation in China
.
At present, Cetrorelix Acetate for injection in the domestic market has only the original research drug and one generic drug, and the competition pattern is good
.
Figure 3: Sales of Cetrorelix Acetate for Injection (Unit: Ten Thousand Yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Meinenet, in 2020, the sales of Cetrorelix Acetate for injection in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) terminals will exceed 200 million yuan.
In the first half of 2021, it has soared by 60%.
As the demand for reproduction continues to increase, the market size of the product is expected to continue to rise
.
In the first half of 2021, it has soared by 60%.
As the demand for reproduction continues to increase, the market size of the product is expected to continue to rise
.
2021 has entered the countdown.
Since this year, Livzon Group has won the production approval of recombinant human chorionic gonadotropin for injection.
Fluvoxamine maleate tablets and omeprazole sodium for injection have passed the consistency evaluation.
Acetic acid for injection Alanorelin microspheres, recombinant human follicle stimulating hormone injection, triptorelin pamoate microspheres for injection, and recombinant anti-human IL-17A/F humanized monoclonal antibody injection have been approved for clinical.
.
.
In 2022, the company has an even better report card
.
Since this year, Livzon Group has won the production approval of recombinant human chorionic gonadotropin for injection.
Fluvoxamine maleate tablets and omeprazole sodium for injection have passed the consistency evaluation.
Acetic acid for injection Alanorelin microspheres, recombinant human follicle stimulating hormone injection, triptorelin pamoate microspheres for injection, and recombinant anti-human IL-17A/F humanized monoclonal antibody injection have been approved for clinical.
.
.
In 2022, the company has an even better report card
.
Source: NMPA official website, CDE official website, Minet database
The review data statistics are as of December 30, if there are any errors or omissions, please correct me
.
.
On December 30, Livzon Group issued an announcement stating that the company’s Class 2 new drug Alanorelin Acetate Microspheres for Injection has been approved for clinical trials, and the indication is prostate cancer.
In addition, according to the data on the NMPA official website, the company’s Acetic Acid for Injection The application for the listing of Xiquruike 4 types of imitations has entered the approval stage, and it is expected to win the second domestic product + first review of the product
.
In addition, according to the data on the NMPA official website, the company’s Acetic Acid for Injection The application for the listing of Xiquruike 4 types of imitations has entered the approval stage, and it is expected to win the second domestic product + first review of the product
.
17 million Xiti new drug clinical approval
17 million Xiti new drug clinical approval Figure 1: Livzon’s latest clinical product information approved
Source: CDE official website
It is reported that Livzon’s Alanorelin Acetate Microspheres for Injection is an improved new drug that has undergone 4 years of research and development.
This product is a gonadotropin releasing hormone agonist injected subcutaneously once a month, which can reduce the frequency and medication of patients.
Burden
.
This product is a gonadotropin releasing hormone agonist injected subcutaneously once a month, which can reduce the frequency and medication of patients.
Burden
.
The company has the approval of Alanorelin Acetate API.
Through the optimization of the dosage form, the company has developed long-acting sustained-release microspheres (Class 2.
2 new drugs).
At the same time, it is researching and developing new indications (Class 2.
4 new drugs).
This time, it has been approved for clinical indications.
For prostate cancer, the follow-up can also apply for the treatment of endometriosis, uterine fibroids, breast cancer, precocious puberty, assisted reproduction and other indications
.
Livzon mentioned in the announcement that up to now, the cumulative direct investment in research and development costs of Alanisterrel Acetate Microspheres for Injection is about 17,818,500 yuan
.
Through the optimization of the dosage form, the company has developed long-acting sustained-release microspheres (Class 2.
2 new drugs).
At the same time, it is researching and developing new indications (Class 2.
4 new drugs).
This time, it has been approved for clinical indications.
For prostate cancer, the follow-up can also apply for the treatment of endometriosis, uterine fibroids, breast cancer, precocious puberty, assisted reproduction and other indications
.
Livzon mentioned in the announcement that up to now, the cumulative direct investment in research and development costs of Alanisterrel Acetate Microspheres for Injection is about 17,818,500 yuan
.
The 60% soaring injection will welcome the second and first domestic review
The 60% soaring injection will welcome the second and first domestic review Picture 2: Livzon's product information for approval
Source: NMPA official website
Livzon’s application for the imitation of Cetrorelix Acetate for injection in Category 4 has recently entered the approval process, and if it is successfully approved, it will become the second domestic company + the first company to review it
.
.
It is reported that Cetrorelix is a synthetic gonadotropin-releasing hormone (GnRH) antagonist (GnRH-A) drug, which prevents premature ovulation in patients undergoing controlled ovarian stimulation, and then performs egg collection and assisted reproductive technology Treatment
.
Studies have shown that Cetrorelix also has a good effect on ovarian cancer, prostate cancer, uterine fibroids, endometriosis and other diseases, and has a preventive effect on benign prostatic hypertrophy and ovarian hyperstimulation syndrome
.
.
Studies have shown that Cetrorelix also has a good effect on ovarian cancer, prostate cancer, uterine fibroids, endometriosis and other diseases, and has a preventive effect on benign prostatic hypertrophy and ovarian hyperstimulation syndrome
.
The original research company of Cetrorelix Acetate for Injection is Merck Serono, which entered the Chinese market in 2010
.
Shenzhen Hanyu Pharmaceutical's 6 types of imitation listing applications were approved in 2018, which is the first imitation in China
.
At present, Cetrorelix Acetate for injection in the domestic market has only the original research drug and one generic drug, and the competition pattern is good
.
.
Shenzhen Hanyu Pharmaceutical's 6 types of imitation listing applications were approved in 2018, which is the first imitation in China
.
At present, Cetrorelix Acetate for injection in the domestic market has only the original research drug and one generic drug, and the competition pattern is good
.
Figure 3: Sales of Cetrorelix Acetate for Injection (Unit: Ten Thousand Yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Meinenet, in 2020, the sales of Cetrorelix Acetate for injection in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) terminals will exceed 200 million yuan.
In the first half of 2021, it has soared by 60%.
As the demand for reproduction continues to increase, the market size of the product is expected to continue to rise
.
In the first half of 2021, it has soared by 60%.
As the demand for reproduction continues to increase, the market size of the product is expected to continue to rise
.
2021 has entered the countdown.
Since this year, Livzon Group has won the production approval of recombinant human chorionic gonadotropin for injection.
Fluvoxamine maleate tablets and omeprazole sodium for injection have passed the consistency evaluation.
Acetic acid for injection Alanorelin microspheres, recombinant human follicle stimulating hormone injection, triptorelin pamoate microspheres for injection, and recombinant anti-human IL-17A/F humanized monoclonal antibody injection have been approved for clinical.
.
.
In 2022, the company has an even better report card
.
Since this year, Livzon Group has won the production approval of recombinant human chorionic gonadotropin for injection.
Fluvoxamine maleate tablets and omeprazole sodium for injection have passed the consistency evaluation.
Acetic acid for injection Alanorelin microspheres, recombinant human follicle stimulating hormone injection, triptorelin pamoate microspheres for injection, and recombinant anti-human IL-17A/F humanized monoclonal antibody injection have been approved for clinical.
.
.
In 2022, the company has an even better report card
.
Source: NMPA official website, CDE official website, Minet database
The review data statistics are as of December 30, if there are any errors or omissions, please correct me
.
.
